Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
     
  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.
     
  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — …

/by
Sandoz extends collaboration agreement to drive cutting-edge digital solutions in global fight against antimicrobial resistance (AMR)
  • Extending existing master services agreement with Ares Genetics, to develop digital platform for development and life cycle management of antibiotics, to January 31, 2025
     
  • Both parties strengthening focus on antibiotic stewardship and planning to engage in AMR surveillance and efforts to repurpose existing antibiotics.
     
  • Collaboration focuses on next-generation sequencing (NGS) and AI-assisted bioinformatics solutions for surveillance and drug repurposing efforts

Basel, April 6, 2022 — …

/by
Sandoz targets growth opportunities in respiratory and complex generics through acquisition of respiratory device company Coalesce
  • Sandoz gains significant capabilities and assets in medical and drug device development that target major growth opportunities in respiratory and complex generics
  • Respiratory diseases are leading cause of death and disability and impose huge financial burden on patients worldwide
  • Acquisition further demonstrates Sandoz commitment to pioneer access for patients

Basel, March 14, 2022 — Sandoz, a Novartis division, announced today that it has successfully acquired the UK-based medical and drug delivery device …

/by
Sandoz launches generic lenalidomide in 19 countries across Europe, expanding access to essential oncology medicine
  • Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines1,4
  • Cost savings from Lenalidomide Sandoz can expand treatment options for patients with haemato-oncology conditions1,2
  • Sandoz is committed to developing and providing generic oncology therapies, to provide patients access to affordable, high-quality …
/by
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Ad hoc announcement pursuant to Art. 53 LR

  • Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)
    • IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)
    • Sandoz sales grew +2% (cc, 0% USD) and core operating income in line with prior year (0% cc, 0% USD)
  • Full year net sales grew +4% (cc, +6% USD) driven by strong Innovative Medicines performance
    • Innovative Medicines (IM …
/by
Novartis delivers mid single digit sales growth, margin expansion and advancement of robust pipeline in 2021

Ad hoc announcement pursuant to Art. 53 LR

  • Q4 sales grew +6% (cc1, +4% USD) and core operating income grew +12% (cc, +9% USD)
    • IM sales grew +7% (cc, +5% USD) and core operating income +15% (cc, +12% USD)
    • Sandoz sales grew +2% (cc, 0% USD) and core operating income in line with prior year (0% cc, 0% USD)
  • Full year net sales grew +4% (cc, +6% USD) driven by strong Innovative Medicines performance
    • Innovative Medicines (IM …
/by
Sandoz submits Marketing Authorization Application for proposed biosimilar trastuzumab to EMA
  • Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.
     
  • Breast cancer is one of most common types of cancer in women, accounting for over 355,000 new cases in 2020 in Europe alone1
     
  • Sandoz has been developing and providing oncology medicines for over 30 years, to expand access to and increase affordability of high quality medicines
     

Basel, December 22, 2021 — Sandoz, a global …

/by
Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA
  • Biologics License Application (BLA) is supported by analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.  
     
  • Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers1,2
     
  • Sandoz continues to build on leading generic and biosimilar oncology portfolio to increase patient access and contribute to sustainability of healthcare systems

…

/by
Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz

Ad hoc announcement pursuant to Art. 53 LR

  • Q3 net sales grew +5% (cc¹, +6% USD)
    • Innovative Medicines grew +7% (cc, +8% USD)
    • Strong performance of key growth drivers: Entresto (+44% cc), Cosentyx (+22% cc), Kesimpta (USD 109 million), Jakavi (+26% cc), Zolgensma (+28% cc), Promacta/Revolade (+18% cc) and Kisqali (+27% cc)
    • Sandoz declined -2% (cc, -1% USD), affected by continued pricing pressures. Ex-US sales grew …
/by
Novartis signs new initial agreement with BioNTech to support fill and finish of the mRNA Pfizer-BioNTech COVID-19 vaccine
  • At least 24 million doses of the mRNA-based vaccine will be filled in 2022 into vials under sterile conditions at Novartis Technical Operations state-of-the-art facility in Ljubljana, Slovenia
  • New agreement follows earlier supply agreement for the fill and finish of more than 50 million doses in 2021 at the Novartis Stein site in Switzerland

Basel, October 21, 2021 — Novartis announced today that it has signed an initial agreement to leverage its manufacturing capacity and capabilities to address the COVID-19 pandemic by expanding …

/by